Report… Barring an unexpected decision from the FDA, GW Pharma, which will hear from the agency by Wednesday, will make history this week when it receives approval for Epidiolex, its oral CBD solution that treats the seizures caused by rare forms of epilepsy....
Here’s the introduction to their piece.. anybody following the market will know that FDA approval is pending and the company are very active in medical states around the US Why Marijuana Stock GW Pharmaceuticals Gained 21% in May What GW Pharmaceuticals...
Here’s their take Cannabis, CBD industry wary of looming decision on epilepsy...
In the first study of its kind for 10 years, researchers from GW Pharmaceuticals, which makes medicines derived from cannabis, and King’s College London found 94% of samples seized by police were varieties with a high psychoactive content, suggesting they dominate the...
Bezinga reports…… The piece in question featured results from GW Pharmaceuticals PLC- ADR GWPH 2.22% and Greenwich Biosciences’ Phase 3 study of Epidiolex — an oral cannabidiol solution — in patients with treatment-resistant Lennox-Gastaut syndrome, or...